ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
-0,01%
Bitcoin
60.810,43
0,03%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Hikma Pharmaceuticals Plc (HIK)

  7. Hikma Pharmaceuticals Plc (HIK) News

HIK

Hikma Pharmaceuticals (HIK)

Hikma Pharmaceuticals Plc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:HIK
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202410h49RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
25/04/202415h28RNS Regulatory NewsHikma Pharmaceuticals Plc Result of AGMLSE:HIKHikma Pharmaceuticals Plc
25/04/202411h15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202411h15Alliance NewsAlliance NewsHikma Pharmaceuticals backs outlook after making strong start to 2024LSE:HIKHikma Pharmaceuticals Plc
25/04/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Trading StatementLSE:HIKHikma Pharmaceuticals Plc
17/04/202411h42RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
15/04/202417h43RNS Regulatory NewsHikma Pharmaceuticals Plc Hikma appoints new President of Generics businessLSE:HIKHikma Pharmaceuticals Plc
11/04/202411h58RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
02/04/202410h50RNS Regulatory NewsHikma Pharmaceuticals Plc Block listing Interim ReviewLSE:HIKHikma Pharmaceuticals Plc
22/03/202410h21RNS Regulatory NewsHikma Pharmaceuticals Plc Annual Financial Report and Notice of AGMLSE:HIKHikma Pharmaceuticals Plc
13/03/202410h42RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
07/03/202414h52RNS Regulatory NewsHikma Pharmaceuticals Plc Director/PDMR ShareholdingLSE:HIKHikma Pharmaceuticals Plc
01/03/202411h17RNS Regulatory NewsHikma Pharmaceuticals Plc Total Voting RightsLSE:HIKHikma Pharmaceuticals Plc
22/02/202410h42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202410h42Alliance NewsAlliance NewsTOP NEWS: Hikma boosts dividend after year of "significant progress"LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h09Alliance NewsAlliance News*Hikma Pharmaceuticals says core operating profit to be in range of USD660m to USD700mLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals expect revenue to grow in the range of 4% to 6%LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h08Alliance NewsAlliance News*Hikma Pharmaceuticals confident that strategy will continue to deliver growth in 2024LSE:HIKHikma Pharmaceuticals Plc
22/02/202408h07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h07Alliance NewsAlliance News*Hikma Pharmaceuticals declares FY dividend of 73 US cents per share vs 56 cents YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 pretax profit USD520m vs USD233m YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h06Alliance NewsAlliance News*REPEAT: Hikma Pharmaceuticals 2023 revenue USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h05Alliance NewsAlliance News*Hikma Pharmaceuticals 2023 USD2.88b vs USD2.52b YoYLSE:HIKHikma Pharmaceuticals Plc
22/02/202408h00RNS Regulatory NewsHikma Pharmaceuticals Plc Final ResultsLSE:HIKHikma Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HIK

Kürzlich von Ihnen besucht

BIT
UV4LLA
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten